Abstract
In chronic lymphocytic leukemia (CLL), therapy-related cytotoxicity and the resulting immunodeficiency are thought to contribute to the development of secondary primary malignancies (SPM). Here, we...
Funding Information
  • Janssen Pharmaceuticals, Inc

This publication has 39 references indexed in Scilit: